More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.59B
EPS
-0.5
P/E ratio
--
Price to sales
20.38
Dividend yield
--
Beta
0.875291
Previous close
$7.63
Today's open
$7.80
Day's range
$7.46 - $7.83
52 week range
$2.08 - $15.37
show more
CEO
Frederick G. Vogt
Employees
975
Headquarters
Philadelphia, PA
Exchange
NASDAQ Global Market
Shares outstanding
462655151
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire • Nov 12, 2026

Iovance Biotherapeutics to Present at Upcoming Conference
PHILADELPHIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conference: 2026 Jefferies Global Healthcare Conference in LondonFireside Chat: November 16, 2026, at 11:00 a.m. GMT / 6:00 a.m.
GlobeNewsWire • Nov 12, 2026

Biotech Is Booming; Here Are 4 Names Outperforming Despite This Deep Correction
I build my biotech investments using technical analysis, focusing on price action and volume, not traditional fundamentals. I target small-cap biotechs advancing past Phase 2, especially those addressing hard-to-treat diseases with novel approaches. Recent regulatory headwinds have eased, derisking select names and enabling ground-floor entry after a sector-wide sell-off.
Seeking Alpha • Nov 9, 2026

Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction
Iovance Biotherapeutics, Inc., delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. IOVA reaffirmed 2026 guidance of $410–$420M revenue, and maintains a robust cash position ($376M) expected to last into 2029. Amtagvi's market-leading durability and expanding treatment center network support its competitive positioning despite intense oncology competition.
Seeking Alpha • Nov 6, 2026

IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress
Iovance reaffirms its 2026 revenue outlook as Q3 sales jump 80%, fueled by Amtagvi adoption, improving margins and progress in its cancer pipeline.
Zacks Investment Research • Nov 6, 2026

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.
Zacks Investment Research • Nov 6, 2026

Iovance: Reset Expectations Make The Stock A Buy Again (Rating Upgrade)
Iovance Biotherapeutics, Inc. fell 46% after my downgrade to Hold in September, reflecting over-optimism in valuation. AMTAGVI's (lifileucel) melanoma launch gained momentum, but the NSCLC opportunity appeared overestimated based on Q2 call signals. Recent NSCLC data showed a 24.6% ORR across 69 evaluable patients, slightly below the prior interim readout.
Seeking Alpha • Nov 6, 2026

Iovance Biotherapeutics Q3 Earnings Call Highlights
Iovance Biotherapeutics NASDAQ: IOVA reported record third-quarter revenue of approximately $122 million, up 80% from a year earlier, as sales of its melanoma treatment AMTAGVI surpassed $100 million in a quarter for the first time.
MarketBeat • Nov 5, 2026

Iovance Biotherapeutics, Inc. (IOVA) Q3 2026 Earnings Call Transcript
Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jen Saunders Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Corleen Roche - Chief Financial Officer Daniel Kirby - Chief Commercial Officer Noah Berkowitz - Chief Medical Officer Raj Puri - Chief Regulatory Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Kuan-Hung Lin - Wells Fargo Securities, LLC, Research Division Nicholas Lorusso - TD Cowen, Research Division Joshua Korsen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Welcome to the Iovance Biotherapeutics Third Quarter 2026 Conference Call.
Seeking Alpha • Nov 5, 2026

Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, and Gross Margin Increased to ~60% 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous Metastatic Non-Small-Cell Lung Cancer (mNSCLC) 59.1% ORR in Biomarker-Selected mNSCLC Subgroup with POSITILITY Trial Underway 55.6% ORR in Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated Liposarcoma (DDLPS) with SARATOGA Registrational Trial Underway PHILADELPHIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported third quarter 2026 financial results, business achievements, and corporate updates. “Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand,” said Frederick Vogt, Ph.D.
GlobeNewsWire • Nov 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Iovance Biotherapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.